Targeting the PD-1 pathway in pediatric solid tumors and brain tumors
Related Experiment Video
Updated: Mar 3, 2026
Establishment of Orthotopic Patient-derived Xenograft Models for Brain Tumors using a Stereotaxic Device
Published on: May 2, 2025
1Division of Pediatric Hematology/Oncology.
Abstract:
While remarkable advances have been made in the treatment of pediatric leukemia over the past decades, new therapies are needed for children with advanced solid tumors and high-grade brain tumors who fail standard chemotherapy regimens. Immunotherapy with immune checkpoint inhibitors acting through the programmed cell death-1 (PD-1) pathway has shown efficacy in some chemotherapy-resistant adult cancers, generating interest that these agents may also be helpful to treat certain refractory pediatric malignancies. In this manuscript we review current strategies for targeting the PD-1 pathway, highlighting putative biomarkers and the rationale for investigation of these drugs to treat common pediatric tumors such as sarcoma, neuroblastoma, and high-grade glioma. We summarize the completed and ongoing clinical trial data available, and suggest potential applications for further study.
Insights
New immunotherapies targeting the programmed cell death-1 (PD-1) pathway show promise for treating advanced pediatric solid tumors and brain cancers. Research is exploring PD-1 inhibitors for difficult-to-treat childhood cancers like sarcoma and neuroblastoma.
Area of Science:
- Pediatric Oncology
- Immunotherapy
- Cancer Research
Background:
- Pediatric leukemia treatments have advanced, but effective therapies for advanced solid tumors and high-grade brain tumors remain limited.
- Immune checkpoint inhibitors targeting the programmed cell death-1 (PD-1) pathway have shown success in adult cancers resistant to chemotherapy.
Purpose of the Study:
- To review current strategies for targeting the PD-1 pathway in pediatric malignancies.
- To highlight biomarkers and the rationale for using PD-1 inhibitors in pediatric cancers.
- To summarize clinical trial data and suggest future research directions.
Main Methods:
- Review of current literature on PD-1 pathway inhibitors.
- Analysis of completed and ongoing clinical trials in pediatric oncology.
- Identification of potential biomarkers for PD-1 targeted therapy.
Main Results:
- PD-1 pathway inhibitors are being investigated for various pediatric tumors, including sarcoma, neuroblastoma, and high-grade glioma.
- Preliminary data suggests potential efficacy in chemotherapy-resistant pediatric cancers.
- Biomarkers are crucial for identifying patients likely to respond to PD-1 blockade.
Conclusions:
- Targeting the PD-1 pathway represents a promising avenue for treating refractory pediatric solid tumors and brain cancers.
- Further clinical investigation and biomarker research are essential to optimize PD-1 inhibitor use in children.
- Immunotherapy offers a potential new treatment modality for challenging pediatric malignancies.
